Stockscreener 앱 받기
6.76
1.05%
0.07
시간 외 거래:
6.75
-0.010
-0.15%
전일 마감가:
$6.69
열려 있는:
$6.95
하루 거래량:
433.90K
Relative Volume:
23.23
시가총액:
$337.96M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+8.68%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$6.75
$7.6999
1주일 범위
$6.04
$7.6999
52주 변동 폭
$5.60
$7.6999
Anbio Biotechnology Stock (NNNN) Company Profile
NNNN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NNNN
Anbio Biotechnology
|
6.76 | 337.96M | 0 | 0 | 0 | 0.00 |
|
ISRG
Intuitive Surgical Inc
|
566.98 | 205.74B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
228.45 | 65.11B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
94.14 | 46.26B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
233.10 | 34.51B | 4.93B | 1.25B | 1.38B | 8.47 |
|
COO
The Cooper Companies, Inc.
|
91.65 | 18.19B | 3.90B | 392.30M | 288.10M | 1.95 |
Anbio Biotechnology 주식(NNNN)의 최신 뉴스
Kestra Medical ups IPO target to $150M - BioWorld Online
Unlocking Anbio's IPO: A Pivotal Shift in Global Diagnostics! - Mi Valle
U.S. IPO Weekly Recap: IPO Calendar Slows Down With Small Listings - Seeking Alpha
IPO NewsUS IPO Weekly Recap: IPO calendar slows down with small listings - Renaissance Capital
Undiscovered Gems In The US Featuring Anbio Biotechnology And 2 Other Small Caps - Yahoo Finance
Anbio Biotechnology prices $8M IPO at $5 per share - MSN
Anbio Biotechnology’s IPO opens up 5% - Investing.com
Anbio Biotechnology’s IPO Set to Revolutionize Global Diagnostics - Mi Valle
NNNNAnbio Biotechnology Latest Stock News & Market Updates - StockTitan
Anbio Biotechnology to Showcase Cutting-Edge Diagnostic Solutions at 2025 Medlab Middle East - PR Newswire
Anbio Biotechnology Unveils Dry Chemiluminescence Immunoassay (CLIA) Solution: Redefining Diagnostic Precision and Efficiency - PR Newswire
Anbio Biotechnology Pursues U.S. IPO For Its IVD Products Launch - Seeking Alpha
Anbio Biotechnology Unveils Comprehensive In-Vitro-Diagnostics Solutions at ADLM 2024 - PR Newswire
Anbio Biotechnology to Showcase at ADLM 2024 with Evolved In Vitro Diagnostic Solutions - PR Newswire
Anbio advances POC testing with new FIA analyzer - SelectScience
Anbio Biotechnology to Showcase ABO & Rhd Blood Grouping Kit at Medlab Middle East 2024 - PR Newswire
Anbio Biotechnology to Present at Medlab Middle East on February 5th, 2024. - PR Newswire
Anbio Biotechnology made a successful first presence at AACC Middle East 2023 - BioSpace
Handheld Analyzer Uses LAMP Diagnostic Technique for Rapid, Point-of-Care Testing - HospiMedica
Anbio Biotechnology Highlights the Future of Diagnostic Solutions at AACC 2023 - PR Newswire
Anbio launches fluorescent immunoassay analyzer for rapid, point-of-care testing - BioWorld Online
Introducing the Anbio LAMP Solution: A Small, Yet Powerful Handheld Analyzer for Rapid, Point-of-Care Testing - PR Newswire
Anbio introduces fluorescent Immunoassay solution for patient care - Medical Device Network
Introducing the Anbio AF-100S: A Small, Yet Powerful Handheld Analyzer for Rapid, Point-of-Care Testing - PR Newswire
Introducing the Anbio ADL i1910: An Elegant CLIA Analyzer for Comprehensive Clinical Testing - PR Newswire
Anbio Biotechnology to Participate in the 2023 AACC Meeting - PR Newswire
AnHeart Therapeutics Raises $61 Million in Oversubscribed Series B Financing to Advance Precision Oncology Pipeline - Business Wire
Anbio Biotechnology (NNNN) 재무 분석
Anbio Biotechnology (NNNN)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
4.97%
1.01%
자본화:
|
볼륨(24시간):